Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid(R)) with Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R2-DHAP).

Trial Profile

Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid(R)) with Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R2-DHAP).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Rituximab
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms R2-DHAP
  • Most Recent Events

    • 08 Aug 2015 Status changed from recruiting to discontinued as per European Clinical Trials Database record.
    • 02 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top